Skip to main content

A Comparison of the Efficacy of Newly Developed Reversible Inhibitors of Acetylcholinesterase with Commonly Used Pyridostigmine as Pharmacological Pre‐Treatment of Soman‐Poisoned Mice

Buy Article:

$43.00 plus tax (Refund Policy)

Abstract:  The ability of three newly developed reversible inhibitors of acetylcholinesterase (AChE) (K298, K344 and K474) and currently available carbamate pyridostigmine to increase the resistance of mice against soman and the efficacy of antidotal treatment of soman‐poisoned mice was compared. Neither pyridostigmine nor new reversible inhibitors of AChE were able to increase the LD50 value of soman. Thus, the pharmacological pre‐treatment with pyridostigmine or newly synthesized inhibitors of AChE was not able to protect mice against soman‐induced lethal acute toxicity. The pharmacological pre‐treatment with pyridostigmine alone or with K474 was able to slightly increase the efficacy of antidotal treatment (the oxime HI‐6 in combination with atropine) of soman‐poisoned mice, but the increase in the efficacy of antidotal treatment was not significant. The other newly developed reversible inhibitors of AChF (K298, K344) were completely ineffective. These findings demonstrate that pharmacological pre‐treatment of soman‐poisoned mice with tested reversible inhibitors of AChF is not promising.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: Department of Toxicology, Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic

Publication date: 2012-04-01

More about this publication?
  • Formerly Pharmacology & Toxicology
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more